Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

HOVON CLL study group

doi:10.1080/10428194.2022.2084731

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

HOVON CLL study group

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

Original language	English
Pages (from-to)	2276-2289
Number of pages	14
Journal	Leukemia and Lymphoma
Volume	63
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2022.2084731
Publication status	E-pub ahead of print - 23 Jun 2022

Bibliographical note

Funding Information:
GR declared consulting fees from Abbvie. MvG declared consulting fee from Janssen, Roche, Gilead, Celgene, Abbvie, Mundipharma, and travel grants from Janssen, Roche, Gilead, Celgene and research funding from Celgene and Roche. SK declared travel grants from Celgene and research funding from Roche, Abbvie and Janssen. MDL declared consulting fee from Roche, Amgen, Janssen, Abbvie and travel grants from Janssen, Roche and Abbvie. RM declared consulting fees from Janssen, Celgene, Gilead, BMC and research grants from Janssen and Gilead. EvdS declared educational fees from Amgen. MB declared educational fee from Janssen. JD declared travel grants from Celgene and Roche. APK declared consulting fee from Janssen, Roche, Abbvie, BMS, Astra Zeneca, LAVA and travel grants from Janssen, Roche, Abbvie, Astra Zeneca and research funding from Roche, Abbvie, Janssen, Astra Zeneca and BMS. The remaining authors declare no conflict of interest for this research work.

Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2022.2084731

Cite this

@article{bbc83d3d92ea4b90ad5079fd5c156b14,

title = "Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group",

abstract = "Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.",

author = "Raa, {Doreen G.Te} and {van der Straten}, Lina and {HOVON CLL study group} and {van Gelder}, Michel and Sabina Kersting and Levin, {Mark David} and Rogier Mous and {van der Straaten}, {Hanneke M.} and Nijziel, {Marten R.} and {van der Spek}, Ellen and Posthuma, {Eduardus F.M.} and Visser, {Hein P.J.} and {van der Klift}, Marjolein and {de Heer}, Koen and Mar Bellido and Doorduijn, {Jeanette K.} and Bruns, {Anke H.W.} and Raijmakers, {Reinier A.P.} and Kater, {Arnon P.}",

note = "Funding Information: GR declared consulting fees from Abbvie. MvG declared consulting fee from Janssen, Roche, Gilead, Celgene, Abbvie, Mundipharma, and travel grants from Janssen, Roche, Gilead, Celgene and research funding from Celgene and Roche. SK declared travel grants from Celgene and research funding from Roche, Abbvie and Janssen. MDL declared consulting fee from Roche, Amgen, Janssen, Abbvie and travel grants from Janssen, Roche and Abbvie. RM declared consulting fees from Janssen, Celgene, Gilead, BMC and research grants from Janssen and Gilead. EvdS declared educational fees from Amgen. MB declared educational fee from Janssen. JD declared travel grants from Celgene and Roche. APK declared consulting fee from Janssen, Roche, Abbvie, BMS, Astra Zeneca, LAVA and travel grants from Janssen, Roche, Abbvie, Astra Zeneca and research funding from Roche, Abbvie, Janssen, Astra Zeneca and BMS. The remaining authors declare no conflict of interest for this research work. Publisher Copyright: {\textcopyright} 2022 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

month = jun,

day = "23",

doi = "10.1080/10428194.2022.2084731",

language = "English",

volume = "63",

pages = "2276--2289",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Diagnosis, treatment and supportive management of chronic lymphocytic leukemia

T2 - recommendations of the Dutch HOVON CLL working group

AU - Raa, Doreen G.Te

AU - van der Straten, Lina

AU - HOVON CLL study group

AU - van Gelder, Michel

AU - Kersting, Sabina

AU - Levin, Mark David

AU - Mous, Rogier

AU - van der Straaten, Hanneke M.

AU - Nijziel, Marten R.

AU - van der Spek, Ellen

AU - Posthuma, Eduardus F.M.

AU - Visser, Hein P.J.

AU - van der Klift, Marjolein

AU - de Heer, Koen

AU - Bellido, Mar

AU - Doorduijn, Jeanette K.

AU - Bruns, Anke H.W.

AU - Raijmakers, Reinier A.P.

AU - Kater, Arnon P.

N1 - Funding Information: GR declared consulting fees from Abbvie. MvG declared consulting fee from Janssen, Roche, Gilead, Celgene, Abbvie, Mundipharma, and travel grants from Janssen, Roche, Gilead, Celgene and research funding from Celgene and Roche. SK declared travel grants from Celgene and research funding from Roche, Abbvie and Janssen. MDL declared consulting fee from Roche, Amgen, Janssen, Abbvie and travel grants from Janssen, Roche and Abbvie. RM declared consulting fees from Janssen, Celgene, Gilead, BMC and research grants from Janssen and Gilead. EvdS declared educational fees from Amgen. MB declared educational fee from Janssen. JD declared travel grants from Celgene and Roche. APK declared consulting fee from Janssen, Roche, Abbvie, BMS, Astra Zeneca, LAVA and travel grants from Janssen, Roche, Abbvie, Astra Zeneca and research funding from Roche, Abbvie, Janssen, Astra Zeneca and BMS. The remaining authors declare no conflict of interest for this research work. Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2022/6/23

Y1 - 2022/6/23

N2 - Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

AB - Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

UR - http://www.scopus.com/inward/record.url?scp=85133778704&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2084731

DO - 10.1080/10428194.2022.2084731

M3 - Review article

C2 - 35737364

AN - SCOPUS:85133778704

SN - 1042-8194

VL - 63

SP - 2276

EP - 2289

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this